Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

George L. Wright(NewYork–Presbyterian Hospital), B. Mayer Grob(NewYork–Presbyterian Hospital), Cara Haley(NewYork–Presbyterian Hospital), Katie Grossman(NewYork–Presbyterian Hospital), Kathy Newhall(NewYork–Presbyterian Hospital), Daniel P. Petrylak(Eastern Virginia Medical School), John K. Troyer(NewYork–Presbyterian Hospital), Alice M. Konchuba(NewYork–Presbyterian Hospital), Paul F. Schellhammer(NewYork–Presbyterian Hospital), Richard P. Moriarty(Eastern Virginia Medical School)
Urology
August 1, 1996
10.1016/s0090-4295(96)00184-7
Cited by 630

Abstract

Related Papers

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.
Timothy J. McDonnell, Patricia Troncoso, Shawn Brisbay et al.|PubMed|1992|1.1k
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
Toshiyuki Miyashita, JC Reed|Blood|1993|876
Activation of Programmed Cell Death in the Rat Ventral Prostate after Castration*
Natasha Kyprianou, John T. Isaacs|Endocrinology|1988|730
Expression of the prostate-specific membrane antigen.
Ron Israeli, C. Thomas Powell, John Corr et al.|PubMed|1994|612
Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.
Marc Colombel, Fraser Symmans, Sixtina Gil et al.|PubMed|1993|595